​

Evommune Stock (NYSE:EVMN)

RevenueOwnershipFinancialsChart
Evommune by TradingView

Previous Close

$23.56

52W Range

$13.88 - $33.20

50D Avg

$23.13

200D Avg

$22.02

Market Cap

$341.78M

Avg Vol (3M)

$396.12K

Beta

0.10

Div Yield

-

EVMN Company Profile

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

45

IPO Date

Nov 06, 2025

Website

EVMN Performance

EVMN Financial Summary

Dec 25Dec 24Dec 23
Revenue$13.00M$7.00M$5.00M
Operating Income$-81.07M$-70.01M$-37.85M
Net Income$-68.87M$-66.81M$-34.05M
EBITDA$-79.68M$-65.49M$-32.99M
Basic EPS$-2.18$-2.27$-1.13
Diluted EPS$-2.18$-2.27$-1.13

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
GLPGGalapagos N.V.
ARTVArtiva Biotherapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
OABIOmniAb, Inc.
CLYMClimb Bio, Inc.
ZYMEZymeworks Inc.
CDXSCodexis, Inc.
LGNDLigand Pharmaceuticals Incorporated
FTREFortrea Holdings Inc.
KPTIKaryopharm Therapeutics Inc.